LOAMU
CLDX icon

Lombard Odier Asset Management (USA)’s Celldex Therapeutics CLDX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,567
Closed -$419K – 426
2025
Q2 		$419K Buy
+20,567
New +$400K 0.03% 237

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s CLDX Position: Q3 2025 in Review

Lombard Odier Asset Management (USA) sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 20,567 shares — an estimated $419K sold.

Lombard Odier Asset Management (USA) first reported a position in CLDX in Q2 2025 and held it in 1 quarter. The position peaked at $419K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Lombard Odier Asset Management (USA) reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 20,567 Celldex Therapeutics shares in Q3 2025, an estimated $419K.
  • Lombard Odier Asset Management (USA) first reported a position in Celldex Therapeutics in Q2 2025 and held it in 1 quarter.
  • Lombard Odier Asset Management (USA)'s Celldex Therapeutics position peaked at $419K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2025, filed 14 Nov 2025.